Visible science

Nicox develops innovative therapeutics to help maintain vision and improve ocular health

Mont Blanc Data and Value Proposition

Learn more about the mechanism of action of NCX 470, our lead product candidate in glaucoma

Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial
May 14, 2025 Read more
Nicox Provides Full Year 2024 Financial Results
April 30, 2025 Read more
Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial
March 19, 2025 Read more